HD-OPM Archive
Topics › Hormones, women's & men's health

Thirty years of trials: raising IGF-1 adds lean mass but not strength in older adults

Louis Nervegna · Jul 24, 2026 · ♥ 1 reactions · 0 comments · original Facebook post
Hormones, women's & men's healthExercise & fitnessAging & longevity
AI summary & key facts

Louis compiles trials of interventions raising circulating IGF-1, such as MK-677, showing reliable gains in lean mass but almost no improvement in strength or function in older adults. He argues the extra lean mass is largely fluid and non-contractile tissue.

Over 30 years of clinical trials in humans have proven that interventions to raise circulating IGF1 do NOT improve muscle quality, strength, or functional capacity in older adults.

Across all these trials, a striking pattern emerges: while raising systemic IGF-1 levels by +50 to +130 ng/mL reliably increases lean body mass (fat-free mass), it almost universally fails to improve muscle strength or physical function in older adults.

The consensus across 30+ years of clinical trials is that increasing systemic IGF-1 expands extracellular fluid and non-contractile lean mass without improving contractile muscle quality, strength, or functional capacity in older adults.

Key Studies Elevating IGF-1 & Testing Muscle Outcomes

(See References section at the end of the post.)

  1. Oral Growth Hormone

Secretagogues (MK-677 / Ibutamoren)

Chapman et al. (1996):

Evaluated daily oral administration of MK-677 (25 mg/day) in 32 healthy older adults (aged 64–81).

Nass et al. (2008):

A 2-year randomized, double-blind, placebo-controlled trial of 25 mg daily MK-677 in healthy older adults (aged 60–81).

  1. Ghrelin Receptor Agonists (Anamorelin)

Dawson-Hughes et al. (2023):

Tested the ghrelin receptor agonist anamorelin in older adults with osteosarcopenia.

  1. Recombinant Human Growth Hormone (rhGH) Injections

Several landmark trials in the 1990s and early 2000s directly administered rhGH to healthy older adults:

Rudman et al. (1990) & Papadakis et al. (1996):

In healthy men over 60–70 years old with low baseline IGF-1 <110 ng/mL, 6 months of rhGH therapy raised mean serum IGF-1 from 105 ng/mL to 230 ng/mL (an increase of +125 ng/mL).

Blackman et al. (2002):

A 26-week trial combining rhGH with or without sex steroid replacement in adults aged 65–88.

Summary Takeaway

If the goal is to significantly increase circulating IGF-1, the GH secretagogues (MK-677, capromorelin) and rhGH reliably achieve this by margins of 50 to 130 ng/mL.

However, the consensus across 30+ years of clinical trials is that increasing systemic IGF-1 expands extracellular fluid and non-contractile lean mass without improving contractile muscle quality, strength, or functional capacity in older adults.

References

Arnarson, A., Geirsdottir, O. G., Ramel, A., Jonsson, P. V., & Thorsdottir, I. (2015). Insulin-like growth factor-1 and resistance exercise in community dwelling old adults. The Journal of Nutrition, Health & Aging, 19(8), 856–860. Insulin-Like Growth Factor-1 and Resistance Exercise in Community Dwelling Old Adults. (J Nutr Health Aging, 2015)

Cited by: 55

Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., Schilling, L. M., Cole, K. Y., Skiles, E. H., Pezzoli, S. S., Hartman, M. L., Veldhuis, J. D., Gormley, G. J., & Thorner, M. O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. The Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral… (J Clin Endocrinol Metab, 1996)

Cited by: 346

Dawson-Hughes, B., Barger, K., Reitshamer, E., Fielding, R. A., Evans, W., & Ceglia, L. (2023). Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With Osteosarcopenia. The Journal of Clinical Endocrinology & Metabolism, 109(3), e945–e955. Effect of Anamorelin, a Ghrelin Receptor Agonist, on Muscle and Bone in Adults With… (The Journal of Clinical Endocrinology & Metabolism, 2024)

Cited by: 6

This post was written in collaboration with Gemeni AI.

#igf1HD #muscleHD #growthhormoneHD #sarcopeniaHD #elderlyHD #peptidesHD

Research cited

← newer: Quoted physician: growth hormone peptides lack evidence for older: Obicetrapib lowered Alzheimer's marker p-tau217, most in APO →